Skip to main content
. 2020 Dec 7;13(1):e12798. doi: 10.15252/emmm.202012798

Figure EV4. In vivo efficacy of EP4 antagonist (TP‐16) combined with immune checkpoint blockade.

Figure EV4

  1. Body weight of mice (CT26 syngeneic tumor model).
  2. The growth of MC38 tumors treated with vehicle, TP‐16 (75 mg/kg, po, daily), anti‐PD‐1 (50 μg, ip, twice weekly), and TP‐16 combined with anti‐PD‐1 antibody (n = 8 per group). Data are presented as mean ± SEM. One‐way ANOVA and Tukey's multiple comparison test were performed; *P < 0.05; **P < 0.01; ***P < 0.001.
  3. Body weight of mice (MC38 syngeneic tumor model).
  4. Representative immunofluorescence staining images of tumor sections from CT26 tumor‐bearing mice stained for myeloid‐derived suppressor cells (MDSCs; CD11b+Gr1+, upper panel) and M2 macrophages (CD11b+CD206+, lower panel). Scale bars, 50 μm.
  5. Cytokines (IL‐6 and CXCL1) in the peripheral blood of CT26 tumor‐bearing mice treated as indicated were measured by enzyme‐linked immunosorbent assay (ELISA) on the last day of treatment (n = 6). One‐way analysis of variance (ANOVA) and Turkey post hoc test were performed, *P < 0.05, **P < 0.01; ***P < 0.001.
  6. Pathway enrichment was analyzed based on the subsets of differentially expressed genes influenced by the combination therapy of TP‐16 and anti‐PD‐1 antibody.

Source data are available online for this figure.